SPINOGENIX, INC.
SPG302, a novel synaptogenic small molecule therapeutic for Alzheimer's disease
- Sector
- Biotech
- Headquarters
- LOS ANGELES, CA
- Founded
- 2016
- Latest Form D
- $10.6M, Mar 2026
- Total capital
- $27.2M
- Federal grants
- $3.3M
- 3 awards · 2018–2024
- Rank in peer group#296 of 514
- Private capital raised
- $23.8M
- 7 Form D · last Mar 2026
- 8 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 30 pending · first 2021
- Rank in peer group#85 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 7th filing$10.6M
- Federal grantHealth and Human S · Phase II · Development of a novel, regenerative therapy to reverse synapse loss in Alzheimer's Disease$1.6M
- Private capital raisedForm D · SEC · 6th filing$2.8M
- Private capital raisedForm D · SEC · 5th filing$5.2M
- Federal grantHealth and Human S · Phase II · Development of a novel, regenerative therapy to reverse synapse loss in Alzheimer's Disease$1.4M
- Private capital raisedForm D · SEC · 4th filing$3.3M
- Private capital raisedForm D · SEC · 3rd filing$1.6M
- Private capital raisedForm D · SEC · 2nd filing$250K
- Private capital raisedForm D · SEC · 1st filing$100K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase I · Novel small molecules that target Alzheimer's disease by increasing spinogenesis and decreasing A-beta toxicity$315K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#85 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Stella SarrafResearcherExecutive Officer, DirectorLinked by 3 patents
- Peter Whitney VanderklishResearcherExecutive OfficerLinked by $3M in grants as PI
- Vincent SimmonResearcherExecutive OfficerLinked by $315K in grants as PI
- Dan Whitney AlbostaExecutive OfficerNamed in SEC Form D filings
- Franz HeftiDirectorNamed in SEC Form D filings
- Jerre L. SteadDirectorNamed in SEC Form D filings
Show all 12 people
- Jerre Whitney SteadDirectorNamed in SEC Form D filings
- Josh SwartzDirectorNamed in SEC Form D filings
- Mervyn Whitney TurnerDirectorNamed in SEC Form D filings
- Mervyn Turner, Ph.D.DirectorNamed in SEC Form D filings
- Stella Sarraf, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Steve YoungDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 34- GrantedMethods Of Treating Spinal Cord Injury Or DamageUSPTOUS 12,734,159
- GrantedSolid Forms Of A Promoter Of SpinogenesisUSPTOUS 12,486,287
- GrantedBenzothiazole And Related CompoundsUSPTOUS 12,391,659
Show all 34 patent records
- Methods Of Treating Spinal Cord Injury Or DamageSep 15, 2026 · US 12,734,159Granted
- Solid Forms Of A Promoter Of SpinogenesisDec 2, 2025 · US 12,486,287Granted
- Benzothiazole And Related CompoundsAug 19, 2025 · US 12,391,659Granted
- Fascin Binding Compounds For SpinogenesisDec 26, 2024 · Application 18629627Pending
- Certain Fascin Binding Compounds For SpinogenesisJun 6, 2024 · Application 18552019Pending
- Methods Of Treating Spinal Cord Injury Or DamageMay 16, 2024 · Application 18277901Pending
- Fascin Binding Compounds For SpinogenesisOct 28, 2021 · Application 17271163Pending
- Benzothiazole And Related CompoundsSep 14, 2021 · US 11,117,878Granted
- Certain Fascin Binding Compounds For SpinogenesisApplication PCTUS2022021507Pending
- Methods Of Treating Spinal Cord Injury Or DamageApplication PCTUS2022016936Pending
- Certain Fascin Binding Compounds For SpinogenesisApplication 63291077Pending
- Methods Of Treating Spinal Cord Injury Or DamageApplication 63287710Pending
- Certain Fascin Binding Compounds For SpinogenesisApplication 63165079Pending
- Methods Of Treating Spinal Cord Injury Or DamageApplication 63152174Pending
- Solid Forms Of A Promoter Of SpinogenesisApplication PCTUS2020015967Pending
- Fascin Binding Compounds For SpinogenesisApplication PCTUS2019048408Pending
- Solid Forms Of A Promoter Of SpinogenesisApplication 62799644Pending
- Fascin Binding Compounds For SpinogenesisApplication 62785435Pending
- Fascin Binding Compounds For SpinogenesisApplication 62726904Pending
- Fascin Binding Compounds For SpinogenesisApplication 62723381Pending
- Benzothiazole And Related CompoundsApplication PCTUS2018044852Pending
- Use Of Benzothiazole Amphiphiles For Treating Traumatic Brain InjuryApplication PCTUS2018039322Pending
- Use Of Benzothiazole Amphiphiles For Treating Traumatic Brain InjuryApplication 62574635Pending
- Benzothiazole And Related CompoundsApplication 62540311Pending
- Use Of Benzothiazole Amphiphiles For Treating Traumatic Brain InjuryApplication 62524758Pending
- Benzothiazole Compound For Treating Or Preventing DiabetesApplication PCTUS2025043614Pending
- Methods Of Dosing Spinogenic CompoundsApplication 19472085Pending
- Methods Of Treating Ophthalmic DiseasesApplication PCTUS2025043607Pending
- Methods For Prevention And Treatment Of DepressionApplication PCTUS2025017952Pending
- Benzothiazole Compound For Treating Or Preventing DiabetesApplication 63687243Pending
- Methods Of Treating Ophthalmic DiseasesApplication 63687234Pending
- Methods Of Dosing Spinogenic CompoundsApplication PCTUS2024022673Pending
- Methods For Prevention And Treatment Of DepressionApplication 63559357Pending
- Methods Of Dosing Spinogenic CompoundsApplication 63456685Pending
Related companies, and why
- Third Harmonic BioSimilar federal contract value in Biotech · null in contracts
- BridgeBio Oncology TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Beam TherapeuticsSimilar federal contract value in Biotech · null in contracts
- OPENCELL TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
- PAMDECA, LLCSimilar federal contract value in Biotech · null in contracts
- ALLYX BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .